首页> 外文期刊>Cancer science. >An IL‐27/Stat3 axis induces expression of programmed cell death 1 ligands (PD‐L1/2) on infiltrating macrophages in lymphoma
【24h】

An IL‐27/Stat3 axis induces expression of programmed cell death 1 ligands (PD‐L1/2) on infiltrating macrophages in lymphoma

机译:IL‐27 / Stat3轴诱导淋巴瘤浸润巨噬细胞上程序性细胞死亡1配体(PD‐L1 / 2)的表达

获取原文
           

摘要

Immune escape and tolerance in the tumor microenvironment are closely involved in tumor progression, and are caused by T-cell exhaustion and mediated by the inhibitory signaling of immune checkpoint molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell immunoglobulin and mucin domaincontaining molecule-3. In the present study, we investigated the expression of the PD-1 ligand 1 (PD-L1) in a lymphoma microenvironment using paraffin-embedded tissue samples, and subsequently studied the detailed mechanism of upregulation of PD-L1 on macrophages using cultured human macrophages and lymphoma cell lines. We found that macrophages in lymphoma tissues of almost all cases of adult T-cell leukemia/lymphoma (ATLL), follicular lymphoma and diffuse large B-cell lymphoma expressed PD-L1. Cell culture studies showed that the conditioned medium of ATL-T and SLVL cell lines induced increased expression of PD-L1/2 on macrophages, and that this PD-L1/2 overexpression was dependent on activation of signal transducer and activator of transcription 3 (Stat3). In?vitro studies including cytokine array analysis showed that IL-27 (heterodimer of p28 and EBI3) induced overexpression of PD-L1/2 on macrophages via Stat3 activation. Because lymphoma cell lines produced IL-27B (EBI3) but not IL-27p28, it was proposed that the IL-27p28 derived from macrophages and the IL-27B (EBI3) derived from lymphoma cells formed an IL-27 (heterodimer) that induced PD-L1/2 overexpression. Although the significance of PD-L1/2 expressions on macrophages in lymphoma progression has never been clarified, an IL-27-Stat3 axis might be a target for immunotherapy for lymphoma patients.
机译:肿瘤微环境中的免疫逃逸和耐受性与肿瘤进展密切相关,由T细胞衰竭引起,并由免疫检查点分子(包括程序性死亡1(PD-1),细胞毒性T淋巴细胞相关蛋白)的抑制性信号传导介导。 4,以及T细胞免疫球蛋白和粘蛋白结构域分子3。在本研究中,我们使用石蜡包埋的组织样本研究了PD-1配体1(PD-L1)在淋巴瘤微环境中的表达,随后研究了培养的人类巨噬细胞对PD-L1在巨噬细胞上调的详细机制。和淋巴瘤细胞系。我们发现,几乎所有成人T细胞白血病/淋巴瘤(ATLL),滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤病例中,淋巴瘤组织中的巨噬细胞均表达PD-L1。细胞培养研究表明,ATL-T和SLVL细胞系的条件培养基诱导巨噬细胞上PD-L1 / 2的表达增加,并且该PD-L1 / 2的过表达取决于信号转导子和转录激活子3的激活( Stat3)。包括细胞因子阵列分析在内的体外研究表明,IL-27(p28和EBI3的异二聚体)通过Stat3激活诱导巨噬细胞上PD-L1 / 2的过表达。由于淋巴瘤细胞系产生IL-27B(EBI3),但不产生IL-27p28,因此有人提出,巨噬细胞来源的IL-27p28和淋巴瘤细胞来源的IL-27B(EBI3)形成了IL-27(异二聚体) PD-L1 / 2过表达。尽管尚未阐明PD-L1 / 2在巨噬细胞进展中在淋巴瘤进展中的重要性,但IL-27-Stat3轴可能成为淋巴瘤患者免疫治疗的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号